Effect of estrone sulfate on postmenopausal bone loss

Harry K. Genant, David J. Baylink, John Christopher G. Gallagher, Steven T. Harris, Peter Steiger, Marilyn Herber

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Estrogen replacement therapy confers many beneficial effects to postmenopausal women, such as slowing the rate of bone loss and decreasing the risk of coronary artery disease. This multicenter, placebo-controlled study evaluated the lowest effective daily dose of estrone sulfate (0.3, 0.625, or 1.25 mg) combined with 1000 mg elemental calcium supplementation for preventing bone loss in the immediate postmenopausal period. Spinal bone mineral density was measured using quantitative computed tomography. Compared with baseline, bone mineral density increased significantly (P <.05) after 12 months of 0.625 mg daily (+1.9%) or 1.25 mg daily (+2.5%). The difference between the 0.625-mg and 1.25-mg doses was not statistically significant. Estrone sulfate administration (0.625 and 1.25 mg) produced significant changes in various lipid measurements at both the 6- and 12-month observation points. The prevalence rates for adverse events were comparable among the estrone sulfate groups and the placebo group. Estrone sulfate 0.625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period.

Original languageEnglish
Pages (from-to)579-584
Number of pages6
JournalObstetrics and Gynecology
Volume76
Issue number4
StatePublished - 1990

Fingerprint

Postmenopausal Osteoporosis
Bone Density
Placebos
Calcium
Postmenopause
Bone and Bones
Estrogen Replacement Therapy
Coronary Artery Disease
Tomography
Observation
Lipids
estrone sulfate

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Genant, H. K., Baylink, D. J., Gallagher, J. C. G., Harris, S. T., Steiger, P., & Herber, M. (1990). Effect of estrone sulfate on postmenopausal bone loss. Obstetrics and Gynecology, 76(4), 579-584.

Effect of estrone sulfate on postmenopausal bone loss. / Genant, Harry K.; Baylink, David J.; Gallagher, John Christopher G.; Harris, Steven T.; Steiger, Peter; Herber, Marilyn.

In: Obstetrics and Gynecology, Vol. 76, No. 4, 1990, p. 579-584.

Research output: Contribution to journalArticle

Genant, HK, Baylink, DJ, Gallagher, JCG, Harris, ST, Steiger, P & Herber, M 1990, 'Effect of estrone sulfate on postmenopausal bone loss', Obstetrics and Gynecology, vol. 76, no. 4, pp. 579-584.
Genant HK, Baylink DJ, Gallagher JCG, Harris ST, Steiger P, Herber M. Effect of estrone sulfate on postmenopausal bone loss. Obstetrics and Gynecology. 1990;76(4):579-584.
Genant, Harry K. ; Baylink, David J. ; Gallagher, John Christopher G. ; Harris, Steven T. ; Steiger, Peter ; Herber, Marilyn. / Effect of estrone sulfate on postmenopausal bone loss. In: Obstetrics and Gynecology. 1990 ; Vol. 76, No. 4. pp. 579-584.
@article{562d6c09b07a4844b56a99ceeadd5406,
title = "Effect of estrone sulfate on postmenopausal bone loss",
abstract = "Estrogen replacement therapy confers many beneficial effects to postmenopausal women, such as slowing the rate of bone loss and decreasing the risk of coronary artery disease. This multicenter, placebo-controlled study evaluated the lowest effective daily dose of estrone sulfate (0.3, 0.625, or 1.25 mg) combined with 1000 mg elemental calcium supplementation for preventing bone loss in the immediate postmenopausal period. Spinal bone mineral density was measured using quantitative computed tomography. Compared with baseline, bone mineral density increased significantly (P <.05) after 12 months of 0.625 mg daily (+1.9{\%}) or 1.25 mg daily (+2.5{\%}). The difference between the 0.625-mg and 1.25-mg doses was not statistically significant. Estrone sulfate administration (0.625 and 1.25 mg) produced significant changes in various lipid measurements at both the 6- and 12-month observation points. The prevalence rates for adverse events were comparable among the estrone sulfate groups and the placebo group. Estrone sulfate 0.625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period.",
author = "Genant, {Harry K.} and Baylink, {David J.} and Gallagher, {John Christopher G.} and Harris, {Steven T.} and Peter Steiger and Marilyn Herber",
year = "1990",
language = "English",
volume = "76",
pages = "579--584",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effect of estrone sulfate on postmenopausal bone loss

AU - Genant, Harry K.

AU - Baylink, David J.

AU - Gallagher, John Christopher G.

AU - Harris, Steven T.

AU - Steiger, Peter

AU - Herber, Marilyn

PY - 1990

Y1 - 1990

N2 - Estrogen replacement therapy confers many beneficial effects to postmenopausal women, such as slowing the rate of bone loss and decreasing the risk of coronary artery disease. This multicenter, placebo-controlled study evaluated the lowest effective daily dose of estrone sulfate (0.3, 0.625, or 1.25 mg) combined with 1000 mg elemental calcium supplementation for preventing bone loss in the immediate postmenopausal period. Spinal bone mineral density was measured using quantitative computed tomography. Compared with baseline, bone mineral density increased significantly (P <.05) after 12 months of 0.625 mg daily (+1.9%) or 1.25 mg daily (+2.5%). The difference between the 0.625-mg and 1.25-mg doses was not statistically significant. Estrone sulfate administration (0.625 and 1.25 mg) produced significant changes in various lipid measurements at both the 6- and 12-month observation points. The prevalence rates for adverse events were comparable among the estrone sulfate groups and the placebo group. Estrone sulfate 0.625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period.

AB - Estrogen replacement therapy confers many beneficial effects to postmenopausal women, such as slowing the rate of bone loss and decreasing the risk of coronary artery disease. This multicenter, placebo-controlled study evaluated the lowest effective daily dose of estrone sulfate (0.3, 0.625, or 1.25 mg) combined with 1000 mg elemental calcium supplementation for preventing bone loss in the immediate postmenopausal period. Spinal bone mineral density was measured using quantitative computed tomography. Compared with baseline, bone mineral density increased significantly (P <.05) after 12 months of 0.625 mg daily (+1.9%) or 1.25 mg daily (+2.5%). The difference between the 0.625-mg and 1.25-mg doses was not statistically significant. Estrone sulfate administration (0.625 and 1.25 mg) produced significant changes in various lipid measurements at both the 6- and 12-month observation points. The prevalence rates for adverse events were comparable among the estrone sulfate groups and the placebo group. Estrone sulfate 0.625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period.

UR - http://www.scopus.com/inward/record.url?scp=0025042559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025042559&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 579

EP - 584

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -